Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up
By Jim Miller
Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-10-02-2004
Volume 28
Issue 10
Big Pharma is ramping up capital spending in parenteral manufacturing at the same time that contract manufacturers are completing their own major investment programs.
Articles in this issue
A Novel Freeze Pelletization Technique for Preparing Matix Pellets
Aseptic Processing: A Review of Current Industry Practice
Can Inserts Be Improved?
Analysis of a Kneading Process to Evaluate Drug Substance-Cyclodextrin Complexation
Drug Development Linked More Closely to Diagnostics
Preparation and In Vitro Characterization of Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 Using Chiral Essential Oil Components
In The Spotlight-October 2004
October 2004
Visible-Residue Limit for Cleaning Validation and its Potential Application in Pharmaceutical Research Facility
The High Price of Success
Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up
USP General Notices and General Test Chapters: Interpretations and Misinterpretations
Breaking the Barrier: Advances in Transdermal Technology
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
